UK markets open in 5 hours 4 minutes

Beam Therapeutics Inc. (BEAM)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
38.71-1.71 (-4.23%)
At close: 04:00PM EDT
39.25 +0.54 (+1.39%)
After hours: 07:50PM EDT
Sign in to post a message.
  • R
    RV
    https://twitter.com/gantzer16/status/1541624705743978497

    Went into $Beam tonight to setup an overnight #ngs run and the motion lights turned off. The new
    @formulatrix
    rover track and
    @HighResBio
    systems look awesome at night.
  • R
    RV
    This is brillant:
    First- CD34 on human hematopoietic stem/progenitor cells
    Unedited CD 34 cells- monoclonal antibody to CD 117 - SCF is displaced to tag to CD 117 - cell does not proliferate but die
    Edited cells- edit CD 34 to escape monoclonal antibody but tag to CD 117- normal signalling preserved for cells to survive and expand.
    highly efficient multi-plex base editing of both our c-kit ESCAPE edit as well as our HBG1/2 edit, resulting in ~60% gamma G induction in IVED cells
  • R
    RV
    The ability to modify CD117 so that the antibodies can clear wild type stem cells, but don't harm the new HSC's is powerful. This is what innovation looks like
    Intuitive. Already looks like something that could be out licensed for even more royalties
  • R
    RV
    From Wei Zhao- He explains it so well:
    A little more brillance from the BEAM TEAM:
    Alky a potent and long half-life conditioning agent may also kill the newly engrafted edited cells, while a less potent one may not kill all old HSCs to make room for the new ones.lating conditioning agents (busulfan), are genotoxic and non-specific.
    So Beam planned to use MGTA-117 for non-genotoxic and HSC-specific conditioning. But the existing CD117 mAb/ADC, including MGTA-117, is not optimized for this selective blocking.
    Beam is developing ESCAPE eHSC by engineering CD117 so that mAb can block SCF binding (critical for the survival and renewal of HSCs) to wtCD117, but not SCF binding to engineered CD117 variants, to enable selectively engraft in the presence of conditioning agent.
    ESCAPE-1 and 2 use two slightly different ABE editors, they cannot use the same engineered CD117 variant. Beam thus identified two such variants (one for each program), both of which can escape mAb-7 binding but otherwise function normally.
    this redoseable mAb-7, which may gradually remove old, unedited HSCs, myeloablative conditioning may no longer be needed or desired.
    If Beam’s strategy works, it will be revolutionary: simultaneously maximizing the efficiency of gene-editing therapy and minimizing the disruption of patients’ immune systems. It is compatible with both ex and in vivo editing approaches and opens the door to other possibilities.
    may help overcome its current major limitation: relatively low delivery efficiency to bone marrow. On the other hand, in vivo may not even be absolutely needed, if non-myeloablative ex vivo can work.
  • R
    RV
    base editing to modify CD117 epitopes on blood stem cells (HSCs), potentially allowing for a conditioning antibody to clear old, diseased cells while allowing new, edited cells to grow.
    A protein found on the surface of many different types of cells. It binds to a substance called stem cell factor (SCF), which causes certain types of blood cells to grow.

    John Evans
    @john_evans3
    ·
    3h
    This is an ideal application for base editing because
    1) we can change just one amino acid to alter antibody binding, without disrupting CD117 function;
    2) we can multiplex this edit with therapeutic edits, such as with our BEAM-101 or BEAM-102 edits in sickle cell disease (SCD).
  • R
    RV
    Engineered VLP to deliver BE to different organs now published - this data was shared with us in the past.
    https://twitter.com/CellCellPress
  • R
    RV
    https://twitter.com/CellCellPress/status/1541438782100180995
    engineered VLP data - published!
    Therapeutics to deliver BE to multiple organs.
  • K
    Kevin
    BEAM & TSLA are up guys!
  • R
    RV
    Wei Zhao:
    impressed by Beam's two new programs: ESCAPE-1/2 (HPFH/MKSR+CD117) to treat SCD. It has the potential to not only get rid of genotoxic conditioning but also increase editing efficiency indirectly by removing un-multi-plex-edited cells for both ex vivo and in vivo delivery.
    there is a possibility that multiplex editing can even become a standard approach to boost editing efficiency for other indications, by using mAb to remove all other un-multi-plex-edited (unmarked) cells in the target organ
    a relatively low in vivo editing efficiency (say ~20%) may be gradually boosted by dosing (or redosing) of anti-CD117 mAbs till edited HSCs reach satisfactory levels (say > 50%).
    Another big advantage is that this ABE-enabled multiplex editing approach cannot be easily copied by other competitors because of Beam's strong IP portfolios for ABE.
  • F
    Frank
    $CRSP conversation
    DO I LOVE $BEAM Yes! DO I LOVE $CRSP YES!. I do believe base editing is the future but CRSP will be first to market and will have the largest cash position to buy up a competitor. So we can argue who will be 1st 2nd but just load up on both for retirement. That and CRBU, NTLA,
  • M
    MUTA
    Beam up 53% from May lows. Market up, Beam up. Market down, Beam up. Market flat, Beam up. Beam just UP. Shorts better be adjusting their diapers right about now. And diapers are getting expensive, so if they didn't stock up last year, they'll be getting rekt by Depends AND by Beam to $150, then $1500.
  • R
    RV
    ESCAPE = “Engineered Stem Cell Antibody Paired Evasion”
    https://twitter.com/john_evans3/status/1541388755281616899
    John Evans
    @john_evans3
    ·
    14m
    This is an ideal application for base editing because
    1) we can change just one amino acid to alter antibody binding, without disrupting CD117 function;
    2) we can multiplex this edit with therapeutic edits, such as with our BEAM-101 or BEAM-102 edits in sickle cell disease (SCD).
  • F
    Frank
    $CRSP conversation
    $CRSP $BEAM $CRBU $NTLA Sure you can debate what one of these will be 1st in the end but these will be the top 4 winners. I say 1st CRSP next 2 years, then beam 1st place after that
  • B
    Brian
    Money managers are bottom feeding in biotech. They are seeing this tech has nothing to do with the economy. Everyone wants healthcare advancements no matter the economy.
  • K
    Kevin
    Are BEAM and NTLA best of the breed???
  • M
    MUTA
    I wonder what Andy is up to. I've been thinking about him today and over the past few days. Is he still hoping that his Beam stock does poorly so that he can spite his own face?
  • M
    MUTA
    We don't know if this is a bear market rally with new lows incoming, but we do know that Beam is much more valuable than $43/share.

    Beam to $150, then $1500.
  • X
    XjdX
    crsp and ntla now both on the record as copying beam's base editing approach. the strongest endorsements are when your competition decides your way is better.
  • A
    Andy
    Come on Muta you need to pump more. Down over 6% right now. Don’t be a slacker.